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Brain metastases are unfortunately very common in the natural history of many solid
tumors and remain a life-threatening condition, associated with a dismal prognosis,
despite many clinical trials aimed at improving outcomes. Radiation therapy options for
brain metastases include whole brain radiotherapy (WBRT) and stereotactic radiosurgery
(SRS). SRS avoids the potential toxicities of WBRT and is associated with excellent local
control (LC) rates. However, distant intracranial failure following SRS remains a problem,
suggesting that untreated intracranial micrometastatic disease is responsible for failure
of treatment. The oral alkylating agent temozolomide (TMZ), which has demonstrated
efficacy in primary malignant central nervous system tumors such as glioblastoma, has
been used in early phase trials in the treatment of established brain metastases. Although
results of these studies in established,macroscopic metastatic disease have been modest
at best, there is clinical and preclinical data to suggest that TMZ is more efficacious at
treating and controlling clinically undetectable intracranial micrometastatic disease. We
review the available data for the primary management of brain metastases with SRS,
as well as the use of TMZ in treating established brain metastases and undetectable
micrometastatic disease, and suggest the role for a clinical trial with the aims of treating
macroscopically visible brain metastases with SRS combined with TMZ to address
microscopic, undetectable disease.
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INTRODUCTION
Among the 1,596,670 Americans diagnosed with cancer in 2011,
between 9.6–50.0% depending will develop one or more brain
metastases during the course of their disease (American Cancer
Society, 2011). Radiation Therapy Oncology Group (RTOG) has
performed multiple studies for patients with brain metastases,
unfortunately with limited progress: brain metastasis remains a
life-threatening condition, associated with a dismal prognosis.
Recursive partitioning analysis of the results from three RTOG
trials (1979 through 1993) divided patients into three prognos-
tic groups, with distinct outcomes: (1) patients with a Karnofsky
Performance Status (KPS) >70 and age less than 65, a con-
trolled primary and the brain as the only site of metastases had
a median survival of 7.1 months; (2) patients with a KPS <70
had a median survival of 2.3 months; (3) all of the other patients
had a median survival of 4.2 months (Gaspar et al., 1997). A
more recent review of the RTOG database has resulted in a new
prognostic classification called Graded Prognostic Assessment
(GPA), which incorporates the number of intracranial metastases
to already identified prognostic factors (Sperduto et al., 2008).
Median survivals range from 2.6 months in the poorest prog-
nostic group (age >60, KPS <70, >3 intracranial metastases,
and extracranial metastases present) to 11 months in the most
favorable prognostic group (age <50, KPS 90–100, 1 intracranial
metastasis present, and absence of extracranial metastases). As the
median survival for the most favorable group in either prognos-
tic classification system continues to be less than 12 months, it is
clear that research to improve this condition is much needed.
This review focuses on the outcomes of brain metastases
treated with stereotactic radiosurgery (SRS), the use of temozolo-
mide (TMZ) in the treatment of brain metastases, and proposes
the addition of systemic treatment with TMZ, with the goal of
altering the course of intracranial disease by treating micrometas-
tases throughout the brain.
THE ROLE OF SRS IN TREATMENT OF LIMITED BRAIN
METASTASES
Traditionally, patients with brain metastases have been treated
with whole brain radiation therapy (WBRT) over the course of
2–3 weeks. As the name implies, this treatment is directed at
both macroscopically visible tumors as well as microscopic tumor
cells throughout the brain, taking advantage of an increased
susceptibility of normal brain cells to repair ionizing radiation-
induced DNA damage compared to tumor cells (Goodhead,
1994), increasing median survivals from 1 to 2 months with
corticosteroids alone to approximately 3–6 months (Patchell,
2003).
Acute side effects fromWBRT are common and include alope-
cia, fatigue, skin erythema, otitis externa, nausea, and headache.
Early delayed and late side effects include tanning of the scalp,
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alopecia, hearing loss, hypopituitarism, neurocognitive decline,
behavioral changes, somnolence syndrome, ataxia, and leukoen-
cephalopathy (Suh, 2010).
SRS is a technique of radiation therapy that allows delivery of
a highly conformal dose of radiation to a precisely defined target
in a single treatment session, using multiple beams that converge
on the center of that target, while limiting dose to surrounding
normal brain tissue because of the steep radiation dose gradi-
ent achieved. Several types of delivery methods are used in SRS,
including cobalt-60–based machines (Leksell Gamma Knife), lin-
ear accelerators, and cyclotrons. Potential benefits for SRS in
the treatment of patients with limited brain metastases include
not interrupting systemic chemotherapy, avoidance of alopecia,
less fatigue, avoiding cognitive decline, convenience of a single
treatment session, and avoidance of leukoencephalopathy (Elliott
et al., 2011).
For patients with brain metastases, SRS offers a minimally
invasive treatment that provides excellent local control (LC) rates.
Numerous studies have shown the benefit of SRS on overall sur-
vival (OS) and LC. In RTOG protocol 9508, Andrews et al. treated
333 patients with 1–3 brain metastases, randomizing between
WBRT alone and WBRT + SRS (Andrews et al., 2004). The
addition of SRS improved LC rates (43% higher risk of local
recurrence without SRS) and median OS in patients with a sin-
gle brain metastasis (6.5 vs 4.9 months). Improved performance
status and decreased steroid use were also reported at six months.
Kondziolka et al. also reported a study of 27 patients random-
ized to WBRT with or without SRS for patients for two to four
brain metastases. The trial was closed early after a significant
interim benefit in LC for WBRT + SRS arm was seen (0 vs 92%)
(Kondziolka et al., 1999).
The use of SRS alone for patients with limited brainmetastases
has been increasing, avoiding use of upfront WBRT. The need for
WBRT in addition to SRS has been examined in several prospec-
tive randomized trials. Aoyama et al. reported a prospective
trial comparing SRS with and without WBRT in 132 patients
with one to four brain metastases, with no improvement seen in
overall or high-functioning survival with the addition of WBRT
(Aoyama et al., 2006). While distant intracranial failure and the
need for salvage treatment were higher with SRS alone, rates of
neurologic death were similar between the two groups (22.8 vs
19.3%). Chang et al. randomized 58 patients to SRS alone vs
SRS plus WBRT in patients with one to three brain metastases
(Chang et al., 2009). The trial was stopped early due to a greater
decline in learning and memory in the group that received
WBRT (52 vs 25%). While more patients in the SRS alone group
required salvage therapies, they also experienced longer median
OS and improved long-term cognitive functioning.
Table 1 summarizes published series using SRS alone for the
treatment of limited brain metastases. While there are no ran-
domized trials vs WBRT, SRS provides excellent local rates, and
comparable OS. Collectively, rates of OS range from 7–13.8
months and LC from 76–94%. Current recommendations for
SRS include treatment of one to four brain metastases, which
are less than 3–4 cm in size. Ideally, patients have controlled
extracranial metastases, excellent performance status, and little
to no mass effect or clinically significant edema associated with
their metastases. A recent ASTRO recommendation regarding the
use of radiotherapeutic management for newly diagnosed brain
metastases has recently been published (Tsao et al., 2012).
Despite adequate LC, the dominant pattern of failure in
many of these series remains distant intracranial progression.
Chitapanarux et al. reported a “regional” progression rate (out-
side treated lesions) of 49% at a median follow-up of 7 months.
In a prospective series of 101 patients, Lutterbach et al found
distant brain progression in 34%, 47%, and 78% at 6, 12, and
24 months, respectively, in patients with brain metastases treated
with SRS only. In their randomized trial of SRS vs SRS + WBRT,
Aoyama et al. reported a 12 month actuarial rate of develop-
ing new intracranial metastases of 64% in patients treated with
SRS alone. Clearly, an opportunity exists to improve these out-
comes, decreasing the need for salvage treatment in patients
failing regionally.
SRS TREATMENT ALONE FOR MORE EXTENSIVE
INTRACRANIAL METASTASES
While SRS has traditionally been recommended for patients with
four or less intracranial lesions, several groups have reported on
Table 1 | Outcomes following SRS alone for limited brain metastases.
Study References Study Patients (n) Lesions (n) Crude LC (%) 1yr LC (%) 2yr LC (%) Median OS (mos) Neurologic
death (%)
Aoyama et al., 2006 PRCT 67 1–4 NR 72.5 NR 7.5 19.3
Lutterbach et al., 2003 PO 101 1–3 92 91 79 7.6 NR
Williams et al., 2009 PO 273 1–2 76 NR NR 10.3 NR
Chitapanarux et al., 2003 PO 41 1–4 NR 68 NR 10 12
Gerosa et al., 2002 R 804 1–3 93 NR NR 13.5 15.6
Kihlstrom et al., 1993 R 160 1–5 94 NR NR 7 9.7
Hasegawa et al., 2003 R 172 1–4 87 79 75 8 16.5
Flickinger et al., 1994 R 116 1 85 NR 67 11 NR
Petrovich et al., 2002 R 458 1–5 NR 90 NR 9 32.6
Elliott et al., 2011 R 109 1–3 93 93 89 13.8 11.9
PRCT, prospective, randomized controlled trial; PO, prospective observational trial; R, retrospective series; NR, not reported.
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the use of SRS alone in patients with more extensive intracra-
nial disease. Bhatnagar et al. reported on the University of
Pittsburgh experience treating four or more intracranial metas-
tases (Bhatnagar et al., 2006). In 205 patients with a median of
five intracranial metastases, they demonstrated that, not only was
SRS feasible in this patient population, but also that SRS seemed
to provide a survival advantage when compared to historic con-
trols in this patient population. Further, total treatment volume
(and not number of metastases) was the only significant factor
associated with local recurrence on multivariate analysis.
In a small retrospective study, Lee et al. reported on 15 patients
with one to twelve non-germ cell epithelial ovarian cancer brain
metastases treated with either SRS alone or WBRT alone (Lee
et al., 2008). While some details of treatment and intergroup dif-
ferences were lacking, the SRS arm had a significantly improved
median survival compared to the WBRT arm (29 vs 6 months).
Suzuki et al. reported on 24 patients with 10 or more intracranial
metastases treated SRS alone (Suzuki et al., 2000). While median
survival was only 2.8 months, none of the patients died of neuro-
logic deterioration. In a larger series of 323 patients with multiple
brain metastases treated with SRS alone, Chang et al. reported
outcomes based on the number of brain lesions (Chang et al.,
2010). Median survival and local tumor control rates were not
significantly different between patients with 1–5, 6–10, 11–15, or
greater than 15 lesions, although patients initially treated for>15
lesions had higher risk of distant intracranial failure.
The saftey of SRS treatment of extensive intracranial metastatic
disease has also been examined. Yamamoto et al. reported on
92 SRS procedures for 80 patients with 10 more treated lesions
per treatment session (Yamamoto et al., 2002). The cumulative
whole brain dose was found to be equivalent to approximately
12 Gy WBRT, well below WBRT doses generally prescribed for
brain metastases (30–40Gy) and below doses associated with
unacceptable toxicity.
MECHANISM OF ACTION OF TMZ AND EXPERIENCE IN
GLIOMAS
TMZ is an orally-available alkylating agent already FDA-approved
for treatment of malignant gliomas. Alkylating agents chemically
modify a cell’s DNA by addition of an alkyl group (a chemical
functional group), irreparably damaging the tumor DNA with
resultant killing of cancer cells. Once absorbed, TMZ requires
conversion to its active metabolite MTIC, which occurs sponta-
neously under physiologic conditions (Danson and Middleton,
2001). Because of its small molecular weight (194 Da), TMZ eas-
ily penetrates the blood-brain-barrier (BBB). It is administered
orally, with almost complete absorption when taken on an empty
stomach. The most commonly seen side effects of TMZ include
hematologic toxicities (thrombocytopenia and granulocytopenia
particularly), fatigue, nausea, vomiting, and constipation (Lens
and Eisen, 2003).
TMZ has been studied for the treatment of anaplastic gliomas
(WHO grade III) and glioblastoma (GBM; WHO grade IV). In a
seminal trial reported by Stupp et al. the addition of TMZ to radi-
ation therapy in the postoperative treatment of GBM increased
median OS from 12.1 to 14.6 months (Stupp et al., 2009). An
improvement was also seen in 2 year survival, with 26.5% of
TMZ plus radiotherapy patients surviving, compared to 10.4%
of patients treated with radiotherapy alone.
PREDICTION OF RESPONSE TO TMZ BY MGMT STATUS
Interestingly, in GBM the effectiveness of this drug is asso-
ciated with silencing of a specific DNA-repair enzyme,
O6-methylguanine–DNA methyltransferase (MGMT). MGMT
rapidly reverses DNA alkylation at the O6 position of guanine by
transferring the alkyl group to the active site of the enzyme itself
(Pegg, 2000). Lack of MGMT in the cell allows accumulation of
O6-alkylguanine in the DNA, which triggers mismatch repair,
thereby inducing DNA damage signaling and eventual cell
death (Weller et al., 2010). A major mechanism of MGMT
regulation is via promoter methylation. The MGMT promoter
lacks constitutive regulatory elements such as TATA box and CAT
box. It does, however, contain a CpG island containing a high
density of CG dinucleotides, which are unmethylated in normal
tissues. In an aberrantly methylated state, methyl-CpG-binding
proteins (such as MeCP2 and MBD2), can bind to the promoter,
leading to alterations of chromatin structure and preventing
binding of transcription factors and silencing of the gene, leading
to resistance to alkylating agents (Nakagawachi et al., 2003).
The MGMT promoter methylation status is the strongest
prognostic factor for outcome in patients with newly diagnosed
glioblastoma and is a powerful predictor of response to alkylating
chemotherapy. Hegi et al. further analyzed the MGMT methyla-
tion status of tumors in the EORTC/NCIC trial reported by Stupp
(Hegi et al., 2005). The 2 year and 5 year survival rates in patients
with a methylated MGMT promoter treated with concomitant
and adjuvant TMZ were 49 and 14%, respectively, while the cor-
responding figures for patients initially treated with radiotherapy
only were 24 and 5%. Of patients with an unmethylated MGMT
promoter, 15 and 8%were alive at 2 years and 5 years, respectively,
after treatment with combined chemoradiotherapy, compared
with 2 and 0% in those initially treated with radiotherapy alone
(Table 2).
DISAPPOINTING RESULTS WITH THE USE OF TMZ IN
PATIENTSWITH ESTABLISHED BRAIN METASTASES
The use of traditional chemotherapeutic agents in the treatment
of brain metastases has been met with much skepticism, largely
due to concerns over the large size or hydrophilic nature of these
compounds and their inability to cross the BBB. As noted above,
TMZ has little difficulty crossing the BBB and has demonstrated
efficacy against primary CNS tumors. For these reasons, the TMZ
alone or in combination with other chemotherapeutic agents has
been used to treat brain metastases in several early phase clinical
trials with modest results (Table 2). Overall response rates are not
overwhelming and range from 4 to 13%, although freedom from
progression rates range from 15 to 44%.
TMZ has also been combined with WBRT for the treatment
of established brain metastases, including two randomized trials,
with equally disappointing results (Table 3). It should be noted,
however, that the majority of these patients were heavily pre-
treated and harbor clinically apparent, often symptomatic, brain
metastases. In the 2 randomized trials, there appeared to be some
benefit to adding TMZ to WBRT. Antonadou et al. reported an
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Table 2 | Results of TMZ treatment for established brain metastases.
References Phase Histology N Dose/Schedule Responses
Schadendorf et al., 2006 II Melanoma 45 125–150mg/m2
D1–7, 15–21 q28d
2 PR (4%)
5 SD (11%)
Siena et al., 2010 II Melanoma, breast,
NSCLC
157 150mg/m2
D1–7, 15–21, q28 or q35d
1 CR
9 PR (6%)
31 SD (20%)
Christodoulou et al., 2001 II Solid tumors 27 150mg/m2
5 days q28d
1 PR (4%)
4 SD (17%)
Neuro status improved in
37% patients
Omuro et al., 2006 I Recurrent/ progressive
brain mets
21 150mg/m2
D1–7, 15–21 q28d
Vinorelbine D1 and D8
2 PR (11%)
6 SD (33%)
Iwamoto et al., 2008 II Solid tumors 38 150mg/m2
D1–7, 15–21 q28d
Vinorelbine D1 and D8
1 CR (3%)
1 PR (3%)
5 SD (13%)
Rivera et al., 2006 I Breast 24 75mg/m2
Capecitabine 1800mg/m2
D1–5, 8–12 q21d
1 CR (4%)
3 PR (13%)
Christodoulou et al., 2005 II Solid tumors 32 150–200mg/m2
D1–5
CDDP 75mg/m2
D1 q28d
1 CR (3%)
9 PR (28%)
5 SD (16%)
Abrey et al., 2001 II Recurrent brain mets 34 150–200mg/m2
D1–5 q28d
2 PR (6%)
5 SD (15%)
PR, partial response; CR, complete response; SD, stable disease.
increased objective response rate of 96% when TMZwas added to
WBRT, compared to 67% with WBRT alone. This was also associ-
ated with a decrease in the need for steroid use 2months following
WBRT (67 vs 91%). While Verger et al. did not find a difference
in PFS or OS, the addition of TMZ to WBRT did decrease the
incidence of neurologic death (69 vs 41%).
INCREASED EFFECT OF CHEMOTHERAPY IN MICROSCOPIC
VERSUS DETECTABLE BRAIN METASTASES
Recent preclinical evidence suggests a role for a different strategy:
after radiosurgery of lesions visible on neuroimaging, treatment
of non-radiologically visible micro-metastases might ultimately
be more successful and delay recurrence at distant sites in the
brain. Dr. Patricia Steeg at NCI has developed data supportive
of this hypothesis and has identified a series of drugs that have
shown some promise in this direction (Gril et al., 2008, 2010,
2011; Qian et al., 2011; Steeg et al., 2011). For example, in the
231-BR brain metastasis model of the human breast cancer cell
line MDA-MB-231, Palmieri et al. demonstrated that the his-
tone deacetylase (HDAC) inhibitor Vorinostat was effective in
preventing new metastases from forming, but had significantly
decreased efficacy against established macrometastases (Palmieri
et al., 2009).
Further, clinical evidence exists supporting this hypothesis
that, while TMZ fails once metastases have established, it can
be an effective adjuvant treatment of microscopic intracranial
metastatic disease (Robins et al., 2006). Choong et al. reported
on the use of TMZ and irinotecan as second-line systemic
therapy for non-small cell lung cancer (Choong et al., 2006).
The authors reported a CNS-relapse rate of only 8%, which
is particularly favorable compared to brain metastases rates of
>30% in comparable patient populations (Tannehill et al., 1997).
Additionally, an earlier study reported a CNS metastasis rate of
only 3% with the use of TMZ alone as salvage therapy for pre-
treated non-small cell lung cancer patients (Adonizio et al., 2002).
Thus, it seems TMZ may be effective in addressing intracranial
micrometastatic disease and delaying clinical manifestation of
these metastases.
OPPORTUNITY FOR CLINICAL TRIAL COMBINING SRS
AND TMZ
We believe the above data reveals an ideal opportunity for com-
bining SRS treatment of clinically apparent brain metastases
and systemic treatment of micrometastatic disease with TMZ.
Available data suggests that treatment of up to 10 brain metas-
tases is feasible and safe, and we will pursue such an approach to
avoid (or delay) the use of WBRT. While macrometastases will be
treated with SRS, systemic treatment with TMZ should address
micrometastases and delay or prevent establishment of further
clinically detectable macrometastases.
Further, as noted above, MGMT status is a powerful predictor
of outcomes in response to treatment in GBM. Recently, a role
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Table 3 | Results with TMZ and WBRT for established brain metastases.
References Histology Phase n Dose/Schedule Response
Mikkelsen et al., 2010 Solid tumors I/II 17 95mg/m2
WBRT 30 Gy
3 PR (18%)
10 SD (59%)
6 mo PFS 18%; median PFS 2.4 mo
Kouvaris et al., 2007
Solid tumors II 33 60mg/m2
D1–15
WBRT 36Gy
7 CR (21%)
11 PR (33%)
5 SD (15%)
Median OS 12
Addeo et al., 2008 Breast, NSCLC II 27 75mg/m2
D1–10 q21–28d
WBRT 30 Gy
2 CR (7%)
11 PR (41%)
Median PFS 6 mos, OS 8.8 mos
Verger et al., 2005 Solid tumors II* 82 ±75mg/m2
WBRT 30 Gy
Randomized ± TMZ
No difference in PFS or OS
Neuro death decreased with TMZ
(69% vs 41%)
Addeo et al., 2007 Solid tumors II 59 75mg/m2
D1–10
WBRT 30 Gy
5 CR (8%)
21 PR (36%)
18 SD (31%)
Improved QoL with TMZ
Antonadou et al., 2002 Solid tumors II∗ 43 ±75mg/m2
D1–5
WBRT 40 Gy
ORR increased (96% vs 67%)
Decreased need for steroids 2 mos
after treatment (67% vs 91%)
Margolin et al., 2002 Melanoma II 31 75mg/m2
Daily × 6 weeks
WBRT 30 Gy
1 CR (3%)
2 PR (6%)
*Randomized phase II trial; PR, partial response; CR, complete response; SD, stable disease; ORR, objective response rate; PFS, progression free survival;
OS, overall survival.
for MGMT status in determining treatment outcomes in brain
metastases has also been described. Wu et al. reported on 86 brain
metastases fromnon-small cell lung cancer (Wu et al., 2010). Both
univariate and multivariate analyses showed that median OS was
significantly longer in patients with positive MGMT expression in
brain metastases (16.5 versus 3.5 months, P < 0.001).
It is possible that only low-MGMT expressing metastases
respond to the drug. To explore this hypothesis, efforts to collect
the original tumor will be undertaken, to measureMGMTexpres-
sion in the primary and investigate its role in predicting response
to TMZ after SRS for brain metastasis.
CONCLUSIONS
LC of established brain metastases treated with SRS has been
excellent; however eventual failure “distantly” in brain is unfortu-
nately extremely common. While results of TMZ for established
intracranial metastases is not overwhelming, there is clinical and
preclinical evidence to suggest it is more effective at addressing
micrometastatic disease and preventing clinical manifestation of
macrometastases. The proposed trial combining SRS with TMZ
represents a model for testing the modification of the course of
clinical disease in the brain. While this approach is not new, it has
never been tested in a prospective, rational, and targeted fashion.
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